Fouqueray B, Paillard F, Baud L
Service d'Explorations fonctionnelles, Hôpital Tenon, Paris.
Presse Med. 1998 Oct 10;27(30):1545-53.
Intracellular dehydration is the major risk in case of a polyuropolydipsic syndrome. Excepting osmotic polyuria, prognosis depends on a possibly progressive functional anomaly of the hypothalamopituitary axis.
Polyuropolydipsia occurs when antidiuretic hormone (ADH) secretion is absent (central diabetes insipidis), the kidney does not respond to ADH (nephrogenic diabetes insipidus) or in case of physiological inhibition of ADH secretion (primary polydipsia).
Dynamic explorations are associated with radioimmunoassay of ADH. They are particularly useful in case of atypical diabetes insipidus and include the water restriction test and a study of the sensitivity to exogenous ADH (dDAVP). The results orient the etiologic diagnosis and allow an evaluation of the fluid intake required as a function of the maximal concentrating capacity of the kidneys.
Treatment is based on ADH analogs (dDAVP). The aim is to obtain a constant antidiuretic effect without hyponatremia or escape. In case of partial central diabetes insipidus, a non-hormone treatment using compounds which increase vasopressin release or its effect on the kidney can be proposed.
对于多尿多饮综合征,细胞内脱水是主要风险。除渗透性多尿外,预后取决于下丘脑 - 垂体轴可能进行性的功能异常。
当抗利尿激素(ADH)分泌缺失(中枢性尿崩症)、肾脏对ADH无反应(肾性尿崩症)或ADH分泌受到生理性抑制(原发性烦渴)时,会发生多尿多饮。
动态检查与ADH放射免疫测定相关。它们在非典型尿崩症的情况下特别有用,包括禁水试验和对外源性ADH(去氨加压素)敏感性的研究。这些结果为病因诊断提供方向,并根据肾脏的最大浓缩能力评估所需的液体摄入量。
治疗基于ADH类似物(去氨加压素)。目的是在不发生低钠血症或抗利尿作用消失的情况下获得持续的抗利尿效果。对于部分中枢性尿崩症,可建议使用增加血管加压素释放或其对肾脏作用的化合物进行非激素治疗。